当前位置:首页 > 报告详情

HARMONY JPM 2025FINAL - Website.pdf

上传人: c** 编号:603986 2025-02-03 25页 2.31MB

1、Copyright 2025 Harmony Biosciences.All rights reserved.43rd AnnualJP Morgan Healthcare ConferenceJ E F F R E Y M.D AY N O,M DJ a n u a r y 1 5,2 0 2 5|S a n F r a n c i s c oForward-Looking StatementsThis presentation includes forwardlooking statements within the meaning of the Private Securities Li

2、tigation Reform Act of 1995.All statements other than statements of historical facts contained in these materials or elsewhere,including statements regarding Harmony Biosciences Holdings,Inc.s(the“Company”)future financial position,preliminary financial results,business strategy and plans and object

3、ives of management for future operations,should be considered forward-looking statements.Forward-looking statements use words like“believes,”“plans,”“expects,”“intends,”“will,”“would,”“anticipates,”“estimates,”“may,”“could,”“might,”“continue,”“potential,”and similar words or expressions in discussio

4、ns of the Companys future operations,financial performance or the Companys strategies,but the absence of these words does not mean that a statement is not forward-looking.These statements are based on current expectations or objectives that are inherently uncertain.These forward-looking statements i

5、nvolve significant risks and uncertainties that could cause the actual results to differ materially from the expressed or implied forwarding-looking statements,including,but not limited to the risk factors discussed under the caption“Risk Factors”in the Companys Annual Report on Form 10-K filed with

6、 the U.S.Securities and Exchange Commission(the“SEC”)on February 22,2024 and its other filings with the SEC.While the Company may elect to update such forward-looking statements at some point in the future,it disclaims any obligation to do so,even if subsequent events cause its views to change.This

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要介绍了Harmony Biosciences Holdings, Inc.在2025年的多个关键催化剂和其对公司的潜在影响。 1. WAKIX(pitolisant)在嗜睡症市场具有超过10亿美元的潜力,2025年预计销售额为8.2亿至8.6亿美元。 2. 2025年,Harmony Biosciences预计将有6个三期临床试验项目,包括WAKIX在嗜睡症、Pitolisant在特发性嗜睡症、BP1.15205(Orexin-2受体激动剂)在睡眠/觉醒障碍、ZYN002(CBD凝胶)在脆弱X综合症、EPX-100(Clemizole)在癫痫等。 3. 2025年,Harmony Biosciences预计将有多个关键催化剂,包括Pitolisant在特发性嗜睡症的新药申请(NDA)决定、BP1.15205的临床前数据展示、ZYN002在脆弱X综合症的三期试验顶线数据等。 4. Harmony Biosciences的管线预计将在未来4年内每年推出一个或多个新产品或适应症。
2025年,Harmony Biosciences的哪些产品有望实现重大收入增长? Harmony Biosciences在2025年有哪些关键催化剂? Harmony Biosciences的WAKIX在嗜睡症市场潜力有多大?
客服
商务合作
小程序
服务号
折叠